News
Novo Nordisk Offers Ozempic at $499 Per Month to Eligible US Cash-Paying Customers
(Reuters) -Novo Nordisk said on Monday it was offering its diabetes drug Ozempic for $499 per month to eligible cash-paying patients with type 2 diabetes in the U.S. via its own pharmacy, a tie-up with telehealth service GoodRx and other platforms.
GoodRx Holdings Inc. (NASDAQ:GDRX) announced that, via a collaboration with Novo Nordisk A/S (NYSE:NVO), all strengths of ...
22hon MSN
Ozempic creator Novo Nordisk will sell weight loss drugs for cheaper through this new partnership
T elemedicine company GoodRx ( GDRX) has been helping Americans find the cheapest way to buy drugs for years. Thanks to a new ...
Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.
Novo Nordisk announced Monday that US patients can now get a month’s supply of Ozempic, the blockbuster diabetes drug, for ...
In today’s CEO Daily: Diane Brady talks to GoodRx CEO Wendy Barnes. The big story: Trump, Putin, and Zelensky headed for ...
The Consumer Product Safety Commission issues a warning about fake Labubu dolls posing a choking risk. The FTC is suing a ticket resale company. Former President Jimmy Carter is honored with a postage ...
Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.
Patients who are prescribed Wegovy or Ozempic can now use GoodRx to access the medications at just $499 a month if they skip ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback